Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.

Abstract

The Cholesterol Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-controlled, angiographic trial testing combined colestipol-niacin therapy in 162 subjects. Two-year results (CLAS-I) showed decreased atherosclerosis progression and increased regression. We now describe a subgroup of 103 subjects treated for 4 years (CLAS-II). Changes in blood lipid, lipoprotein-cholesterol, and apolipoprotein levels were maintained, and at 4 years significantly more drug-treated subjects demonstrated nonprogression (52% drug- vs 15% placebo-treated) and regression (18% drug- vs 6% placebo-treated) in native coronary artery lesions. Significantly fewer drug-treated subjects developed new lesions in native coronary arteries (14% drug- vs 40% placebo-treated) and bypass grafts (16% drug- vs 38% placebo-treated). These results confirm CLAS-I findings and indicate that regression can continue for 4 years. They reaffirm the need for early initiation of vigorous long-term lipid lowering therapy in coronary bypass subjects.

• Authors: L Cashin-Hemphill, W J Mack, J M Pogoda, M E Sanmarco, S P Azen, D H Blankenhorn
• Journal: JAMA (JAMA) Vol. 264 Issue 23 Pg. 3013-7 (Dec 19 1990) ISSN: 0098-7484 [Print] United States
• PMID: 2243429 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Apolipoproteins
• Lipids
• Niacin
• Cholesterol
• Colestipol

Topics

• Adult
• Apolipoproteins (blood)
• Cholesterol (blood)
• Colestipol (administration & dosage, therapeutic use)
• Coronary Artery Disease (blood, diagnostic imaging, drug therapy)
• Drug Therapy, Combination
• Follow-Up Studies
• Humans
• Hypercholesterolemia (blood, drug therapy)
• Lipids (blood)
• Male
• Middle Aged
• Niacin (administration & dosage, therapeutic use)
• Radiography